China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
87 hedge funds and large institutions have $1.53B invested in China Biologic Products Holdings, Inc. in 2020 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 33 increasing their positions, 31 reducing their positions, and 17 closing their positions.
354% more call options, than puts
Call options by funds: $20.9M | Put options by funds: $4.6M
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
12% more capital invested
Capital invested by funds: $1.36B → $1.53B (+$168M)
6% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 31
4% less funds holding
Funds holding: 91 → 87 (-4)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capstone Investment Advisors
New York
|
+$53.7M |
| 2 |
Renaissance Technologies
New York
|
+$23.6M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$19.1M |
| 4 |
Millennium Management
New York
|
+$13.8M |
| 5 |
YCMGA
York Capital Management Global Advisors
New York
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SGCM
Sand Grove Capital Management
London,
United Kingdom
|
-$35.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.42M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$7.22M |
| 4 |
MCP
Maso Capital Partners
Hong Kong
|
-$7.11M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$6.46M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QT
101
Quantbot Technologies
New York
| – | -$72K | -709 | Closed |
|
102
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$20K | -200 | Closed |
|
|
PAM
103
Panagora Asset Management
Boston,
Massachusetts
| – | -$9K | -91 | Closed |
|
104
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$6K | -63 | Closed |
|
CBPO Hedge Fund Activity: Q3 2020 in Review
87 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q3 2020, worth a combined $1.53B — up 12% from $1.36B a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CBPO and 14 opened new positions — a net loss of 3 holders — while 31 trimmed existing stakes and 33 added.
The largest buyer was Capstone Investment Advisors, opening a new position worth an estimated $53.7M. The largest seller was Sand Grove Capital Management, exiting entirely with an estimated $35.9M sold.
- 87 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q3 2020, down from 91 in Q2 2020.
- Funds reported $1.53B of China Biologic Products Holdings, Inc. stock for Q3 2020, up 12% quarter-over-quarter.
- 14 funds opened new China Biologic Products Holdings, Inc. positions in Q3 2020 and 17 closed out, a net change of -3 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q3 2020 was Capstone Investment Advisors, an estimated $53.7M added.
- The largest China Biologic Products Holdings, Inc. seller in Q3 2020 was Sand Grove Capital Management, an estimated $35.9M sold.
Based on aggregated 13F filings for Q3 2020.